Advanz Pharma
As of the edition of 20 October 2026, Advanz Pharma runs 17 drugs, 16 of them marketed; it is on route A at 1 target and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 16 |
| Went quiet | 1 |
| Total | 17 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Hydroxychloroquine | none listed | 0 |
| Prednisolone | none listed | 6 |
| Digoxin | none listed | 0 |
| Zonisamide | none listed | 10 |
| Pilocarpine | none listed | 2 |
| Alfuzosin | none listed | 0 |
| Cefepime | none listed | 0 |
| Miglustat | none listed | 2 |
| Alitretinoin | none listed | 0 |
| Tranylcypromine | none listed | 4 |
| Vernakalant | none listed | 5 |
| Nilutamide | none listed | 2 |
| Prednisolone phosphoric acid | none listed | 2 |
| Enmetazobactam | none listed | 0 |
| Phenoxybenzamine | none listed | 3 |
| Triamterene | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 1 target, route B at 4 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Advanz Pharma needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Heart and blood vessels: 8 trials led
- Digestive system: 1 trials led
- Pregnancy and women's health: 1 trials led